Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Long-term Potentiation01:35

Long-term Potentiation

59.3K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
59.3K
Long-term Potentiation01:25

Long-term Potentiation

3.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-related quality of life in adults receiving home parenteral nutrition: A multi-centre cross-sectional study.

Clinical nutrition ESPEN·2026
Same author

Optimizing clinic consultations in primary biliary cholangitis: International consensus recommendations.

Hepatology communications·2025
Same author

Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases.

The lancet. Gastroenterology & hepatology·2025
Same author

Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis.

Orphanet journal of rare diseases·2025
Same author

Identifying Molecular Properties of Ataxin-2 Inhibitors for Spinocerebellar Ataxia Type 2 Utilizing High-Throughput Screening and Machine Learning.

Biology·2025
Same author

Development of a Question Prompt List for People Living With Primary Biliary Cholangitis: A Delphi Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K

Early Relapsing Multiple Sclerosis.

David E Jones

    Continuum (Minneapolis, Minn.)
    |June 5, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Choosing disease-modifying therapies for early relapsing multiple sclerosis (MS) is complex due to varied risks and limited comparative data. Careful patient selection and ongoing monitoring are crucial for effective MS management.

    More Related Videos

    Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
    26:48

    Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

    Published on: July 4, 2007

    18.9K
    Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
    05:55

    Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

    Published on: December 1, 2023

    1.4K

    Related Experiment Videos

    Last Updated: Mar 20, 2026

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
    10:46

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

    Published on: December 9, 2015

    11.2K
    Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
    26:48

    Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

    Published on: July 4, 2007

    18.9K
    Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
    05:55

    Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

    Published on: December 1, 2023

    1.4K

    Area of Science:

    • Neurology
    • Immunology

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Early relapsing MS is characterized by recurrent neurological episodes and lesion formation.

    Purpose of the Study:

    • To present an evidence-based strategy for managing patients with early relapsing multiple sclerosis (MS).

    Main Methods:

    • Review of numerous clinical trials on disease-modifying therapies (DMTs) for relapsing MS.
    • Analysis of DMT efficacy in reducing relapses, MRI lesions, and potentially slowing disability progression and brain atrophy.

    Main Results:

    • DMTs are effective in reducing relapses and new MRI lesions in relapsing MS.
    • Some DMTs may delay disability progression and slow brain atrophy, but few improve existing symptoms or disability.
    • Available DMTs include interferons, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, and alemtuzumab.

    Conclusions:

    • Selecting the optimal DMT for MS is challenging due to varying risks, limited head-to-head trials, and lack of predictive biomarkers.
    • Patient-specific factors, including disease course prediction, risk tolerance, and care partner input, are vital for treatment decisions.
    • Vigilance for breakthrough disease and incorporating symptom management and wellness are essential components of MS care.